Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Michael James Burke MD
Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics
Leukemia & Lymphoma Program Director
Developmental Therapeutics Program Co-Director
Director of Translational & Clinical Research

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
09/1989 - 12/1993 B.S., Biological Sciences, University of California at Irvine, Irvine, CA
01/1996 - 02/2000 M.D., Ross University School of Medicine, Portsmouth, Dominica

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
07/2000 - 06/2001 Intern, Pediatrics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
07/2001 - 06/2003 Resident, Pediatrics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
07/2003 - 06/2006 Fellow, Pediatrics, Hematology/Oncology, Northwestern University Feingold School of Medicine, Children's Memorial Hospital, Chicago, IL

FACULTY APPOINTMENTS:
07/2006 - 05/2013 Assistant Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN
05/2013 - 07/2013 Associate Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN
08/2013 - Present Associate Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Medical College of Wisconsin, Milwaukee, WI
2013 - Present Attending Physician, Pediatrics, Hematology/Oncology/Transplant, Children's Hospital of Wisconsin, Milwaukee, WI
2015 - Present Attending Physician, Pediatrics, Hematology/Oncology, Froedtert Memorial Lutheran Hospital, Milwaukee, WI
07/2020 - Present Professor of Pediatrics, Pediatrics, Pediatric Hematology/Oncology, The Medical College of Wisconsin-Children’s Hospital of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
2007 - 2012 Fellowship Director, Pediatric Hematology/Oncology and Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN

HOSPITAL STAFF PRIVILEGES:
2006 - 2013 Attending Physician, Pediatric Hematology/Oncology, Hennepin County Medical Center (HCMC), Minneapolis, MN
2006 - 2013 Attending Physician, Pediatric Hematology/Oncology, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN
2013 - Present Attending Physician, Pediatric Hematology/Oncology, Children's Hospital of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Pediatrics
2003
2023
ABP - Hematology/Oncology
2006
2026
 
Certificates
Issued By Issue DateExpiration
Neonatal Resuscitation
2000
2007
ECFMG
2000
None
Pediatric Adv. Life Support
2000
2008
 

Licensure
Number Issue DateExpiration
Illinois License
06/24/2003
07/31/2008
Minnesota License
48856
09/09/2006
05/31/2014
Wisconsin License
60869-20
05/31/2013
10/31/2021
 

AWARDS AND HONORS:
1989 - 1993 Zabish Memorial Scholarship Recipient, Undergraduate Academic Scholarship.
1991 National Champion - Men's Light Weight Double Scull, American Rowing Championships, Camden, NJ
2000 Magna Cum Iaude, Ross University School of Medicine
2009 - Present Best Doctors in America
2010 - Present Cambridge Who's Who
06/18/2015 Inducted into The Ring of Honor, Mater Dei High School
2015 - 2020 Milwaukee Magazine Top Doctors - Pediatric Hematology/Oncology

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2000 - Present American Academy of Pediatrics
2004 - Present American Society of Pediatric Hematology and Oncology
2004 - Present American Society of Hematology
2006 - Present Children's Oncology Group (Full member)
2007 - Present Pediatric Bone Marrow Transplant Consortium (PBMTC)
2007 - 2012 American Academy of Pediatrics: Section on Young Physicians
2007 - Present Center for International Blood & Marrow Transplant (CIBMTR)

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2006 - 2013 Member, Hematology/Oncology Fellowship Committee, University of Minnesota Pediatric
2006 - 2013 Co-Chair, Pediatric Leukemia Program, University of Minnesota
2006 - 2007 Member, Pediatric Residency Selection Committee, University of Minnesota
2007 - 2009 Member, Cancer Protocol Review Committee (CPRC) - Non Therapeutic Intervention (NTI) Committee, University of Minnesota
2007 - 2012 Chair, Pediatric Hematology/Oncology Fellowship Committee, University of Minnesota
2007 - 2012 Member, Pediatric Fellowship Committee, University of Minnesota
2008 - 2010 Member, Pediatric Resuscitation Committee, University of Minnesota
2009 - 2013 Co-Chair, Masonic Cancer Center ALL Committee, University of Minnesota
2009 - 2013 Member, Masonic Cancer Center, University of Minnesota
2012 - 2013 Member, Pediatric Hematology/Oncology Faculty Position Search Committee, University of Minnesota
2013 - 2018 Committee Member, Pediatric Hematology/Oncology fellowship Committee, Medeical College of Wisconsin
2013 - Present Director, Pediatric Leukemia and Lymphoma Program, Medical College of Wisconsin/Children's Hospital of Wisconsin
2013 - 2017 Committee Member, Pediatric Developmental Therapeutics Program, Medical College of Wisconsin - Children's Hospital of Wisconsin
2014 - Present Committee Member, Clinical Research Seed Grant Review Committee, Medical College of Wisconsin Cancer Center
2014 - Present Member, Pediatric Intern Selection Committee, Children's Hospital of Wisconsin
2017 - 2020 Member, Cancer Center Pilot Grant Review Committee, Medical College of Wisconsin
2017 - Present Program Co-Director, Pediatric Developmental Therapeutics Program, Medical College of Wisconsin/Children's Hospital of Wisconsin
2017 Grant Reviewer Committee Member, Advancing a Healthier Wisconsin Endowment Research and Education Program, Medical College of Wisconsin
2018 - Present Director, Director of Clinical and Translational Research, Children's Hospital of Wisconsin - Division of Hematology/Oncology/Bone and Marrow Transplantation

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2006 - 2007 Committee Member, Very High Risk ALL, Children's Oncology Group
2007 - 2013 Committee Member, ALL Working Group, Center for International Blood and Marrow Transplant Research (CIBMTR)
2007 - Present Committee Member, High Risk ALL, Children's Oncology Group
2007 - 2013 Committee Member, Pediatric Cancer Working Group, Center for International Blood anqd Marrow Transplant Research (CIBMTR)
2007 - 2013 Committee Member and ALL Liaison, Young Investigators Committee, Children's Oncology Group
2008 - 2012 Committee Member, Oncology Strategy Group, Pediatric Bone Marrow Transplant Consortium (PBMTC)
2008 - 2013 Committee Member, UMN Institutional PI, Treatment Advances in Childhood Leukemia & Lymphoma (TACL)
2009 - Present Study Chair, TACL T2009-003, A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
2009 - 2011 Committee Member, AALL08P1:Intensified PEG-Asparaginase in High-Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study, COG - Committee, Children's Oncology Group
2009 - 2011 Committee Member, ADVL0413 A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias, Childrens Oncology Group
2010 - 2013 Study Chair, ADVL0911 Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-011), Childrens Oncology Group
2010 - 2012 Committee Member, ALL Relapse Task Force, Childrens Oncology Group
2011 - 2019 Study co-chair, AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789) NSC#606869) in the Very High Risk Stratum, Childrens Oncology Group
2012 - Present Member, TACL Steering & Prioritization Committee, Medical College of Wisconsin
2012 - Present Member, TACL Steering Committee, Medical College of Wisconsin
2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Onyx Pharmaceuticals
2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Jazz Pharmaceutical
2013 - Present Member/PI, TACL MCW Institutional PI, Medical College of Wisconsin
2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Seattle Genetics Inc.
2015 - Present Study Chair, Phase Ib Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia, TACL/AMGEN
2015 - Present Committee Member, Chronic Myeloid Leukemia (CML) Working Group, Children's Oncology Group (COG)
2015 - Present Committee Member, Acute Lymphoblastic Leukemia (ALL) Clinical Studies, American Society of Hematology (ASH) Meeting Abstract Reviewer
2015 - Present Abstract Reviewer, Acute Lymphoblastic Leukemia (ALL) Clinical Studies, American Society of Hematology (ASH) Meeting
2016 - Present Ad-Hoc Consultant for Oncologic Drug Advisory Committee (ODAC), U.S. Food and Drug Administration (FDA)

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Children's Oncology Group Chair's Grant Project: 021041 COG AALL1131-High Risk B-Precursor ALL Trial
Source:
Children's Hospital of Philadelphia/NIH (Prime), U10 CA098543
Role:
Principal Investigator, Co-Chair
PI:
Michael Burke
Dates:
03/01/2011 - 02/28/2018
Direct Funds:
$25,000 (costs/current year $25,000; direct costs/project period $25,000)
 
Title:
Phase Ib/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UKR3 Induction backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
Source:
Onyx Pharmaceuticals, Inc.
Role:
PI
PI:
Michael Burke
Dates:
12/11/2014 - 10/03/2018
 
Title:
Epigenetic Reprogramming in Relapse AML
Source:
Go Bo Foundation
Role:
Principal Investigator
PI:
Michael Burke
Dates:
05/29/2015 - 05/28/2018
Direct Funds:
$75,000 ($25,000/year for 3 years)
 
Title:
Phase I study of lentivirus engineered autologous acute myeloid leukemia (AML) cells expressing IL-12 in children and young adults with relapsed AML
Source:
Alex’s Lemonade Stand Foundation for Childhood Cancer: REACH Grant
Role:
Principal Investigator
PI:
Michael Burke, MD
Dates:
02/01/2018 - 01/31/2019
Direct Funds:
$125,000
 
Title:
Phase I study of lentivirus engineered autologous acute myeloid leukemia (AML) cells expressing IL-12 in children and young adults with relapsed AML
Source:
Snowdrop Foundation WI
Role:
Principal Investigator
PI:
Michael Burke
Dates:
02/01/2020 - 01/31/2021
Direct Funds:
$80,000
 
Pending
Peer Review
Title:
NIH COG Chair Grant (U10CA098543) – Project: AALL1131-High Risk B-Precursor ALL Trial
Source:
Children’s Hospital of Philadelphia/NIH NCI
Role:
Study Co-Chair
PI:
Adamson
 
Prior
Peer Review
Title:
Children's Oncology Group (COG) COG ADVL0413: A Phase I/II study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in children with refractory solid tumors or refractory leukemias.
Role:
Study Committee Member
Dates:
2006 - 2012
 
Title:
Clinical Research Studies in Collaboration with the Institute for Pediatric Clinical Research, Therapeutic Advances in Childhood Leukemia (TACL) Consortium
Source:
Children's Hospital Los Angeles
Role:
Principal Investigator (UMN PI for Consortium)
PI:
Michael Burke
Dates:
01/29/2009 - 01/28/2013
Direct Funds:
$7,937
 
Title:
A Therapeutic Trial of Decitabine and SAHA (Vorinostat) in Combination with Standard Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Source:
University of Minnesota, Cancer Experimental Therapeutics Initiative (CETI)
Role:
Principal Investigator
PI:
Michael Burke
Dates:
04/01/2009 - 03/31/2016
Direct Funds:
$175,333
 
Title:
COG Phase I (ACTNOW)/Protocol ADVL0911 ARRA Supplement: A Phase 1 Dose Escalated Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus in Relapsed/Refractory Pediatric Patients with Neuroblastoma Rhabdomyosarcoma, Ewing Family of Tumors, and Rare Tumors with Neuroendocrine Features
Source:
National Childhood Cancer Foundation/NIH Prime, U01 CA097452
Role:
Site Principal Investigator
PI:
Michael Burke
Dates:
06/01/2009 - 05/31/2012
Direct Funds:
$103,516
 
Title:
Children’s Oncology Group (COG) COG ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley (NTX-010), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features.
Role:
Study Chair
Dates:
2009 - 2012
 
Title:
T2008-002 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Source:
Children's Hospital Los Angles
Role:
Site Principal Investigator
PI:
Michael Burke
Dates:
06/18/2010 - 01/28/2013
Direct Funds:
$9,286 (cost/to date: $1,587; costs/project period: $9,286 (pending full enrollment))
 
Title:
T2009-002 Clofarabine with Cytarabine for MRD Positive Leukemia
Source:
Children's Hospital of Los Angeles
Role:
Site Principal Investigator
PI:
Michael Burke
Dates:
09/09/2010 - 01/28/2015
Direct Funds:
$11,111 (costs/to date: 1,250; costs/project period: 11,111 (pending full enrollment))
 
Title:
A therapeutic Trial of Bortezomib (Velcade), SAHA (Vorinostat) and Dexmethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Source:
Millennium Pharmaceuticals, Inc
Role:
Principal Investigator
PI:
Michael Burke
Dates:
09/16/2010 - 06/30/2014
Direct Funds:
$234,813 (costs/to date: $58,703; costs/project period $234,813)
 
Title:
Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic Project: Relapsed Pediatric Acute Lymphoblastic Leukemia
Source:
Mayo Clinic Rochester/NIH/NCI (Prime) K12 CA090628
Role:
Principal Investigator, K12 Scholar
PI:
Michael Burke
Dates:
06/01/2011 - 06/30/2013
Direct Funds:
$269,192 (costs/current year: 134,596; costs/project period $269,192)
 
Title:
A Phase II Trial Investigating Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Source:
University of Minnesota Children's Cancer Research Fund
Role:
Principal Investigator
PI:
Michael Burke
Dates:
07/01/2011 - 12/31/2013
Direct Funds:
$25,000 (cost/current year: $25,000; costs/project period: $25,000)
 
Title:
Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic Project: Relapsed Pediatric Acute Lymphoblastic Leukemia
Source:
K12 CA090628
Role:
K12 Scholar
PI:
Jatoi / M. Burke
Dates:
07/01/2011 - 06/30/2013
 
Title:
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
Source:
R21 CA161688
Role:
Co-PI
PI:
Michael Burke
Dates:
09/01/2011 - 08/31/2013
 
Title:
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
Source:
NIH/NCI, R21 CA 161688
Role:
Principal Investigator
PI:
Michael Burke
Dates:
09/01/2011 - 08/31/2014
Direct Funds:
$612,868 (costs/current year: $306,040; costs/project period: $612,868)
 
Title:
Children’s Oncology Group (COG) COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High-Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High-Risk Stratum.
Role:
Study Co-Chair
Dates:
2011 - 2015
 
Title:
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia
Source:
University of Minnesota Academic Health Center, Faculty Research Development Grant Program
Role:
Principal Investigator
PI:
Michael Burke
Dates:
01/01/2012 - 12/31/2013
Direct Funds:
$200,000 (costs/current year: $102,2013; costs/project period: $200,000)
 
Title:
Functional Analyses of ALL Susceptibility Variants in Hematopoiesis
Source:
University of Minnesota Children's Cancer Research Fund
Role:
Co-Investigator
Dates:
01/01/2012 - 12/31/2013
Direct Funds:
$200,000 (costs/current year: $100,000; costs/project period: $200,000)
 
Title:
Myelodysplastic Syndrome: Bench to Bedside
Source:
Minnesota Partnership for Biotechnology and Genomics Project #11.25
Role:
Consultant
Dates:
02/01/2012 - 01/31/2014
Direct Funds:
$1,213,472
 
Title:
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia
Source:
NIH/NCI R01 CA163864
Role:
Co-Investigator (Years 1-3)
Dates:
09/17/2012 - 06/30/2017
Direct Funds:
$1,037,500 ($1,037,500 (costs/current year: 207,500; costs project period $1,037,500))
 
Title:
Mechanisms of Anticancer Agents Selective Against Drug Resistant Leukemia
Source:
NIH/NCI R01 CA163864
Role:
Co-Investigator (years 1-3)
Dates:
09/17/2012 - 06/30/2017
Direct Funds:
$1,037,500 (costs/current year: 207,500; costs/ project period $1,037,500)
 
Title:
Epigenetic Reprogramming in Relapse AML
Source:
Medical College of Wisconsin Cancer Center
Role:
Principal Investigator
PI:
Michael Burke, MD
Dates:
11/01/2014 - 10/31/2015
Direct Funds:
$50,000
 
Title:
Epigenetic Reprogramming in Relapse AML
Source:
The Medical College of Wisconsin Cancer Center - Advancing Healthier Wisconsin Partnership Program
Role:
PI
PI:
Michael Burke
Dates:
11/01/2014 - 10/31/2016
 
Title:
A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents and Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease
Source:
Snowdrop Foundation - Wisconsin
Role:
Principal Investigator
PI:
Michael Burke, MD
Dates:
01/01/2015 - 12/31/2016
Direct Funds:
$21,000
 
Title:
A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease.
Source:
Children's Research Institute - Snowdrop Foundation (Wisconsin)
Role:
PI
PI:
Michael Burke
Dates:
01/01/2015 - 12/31/2016
 
Title:
Study Chair: NIH National Clinical Trials Network (NCTN) Grant U10CA180886 successor to NIH COG Chair Grant (U10CA098543).
Source:
Children’s Hospital of Philadelphia/NIH NCI
Role:
Study Co-Chair
PI:
Adamson
Dates:
03/01/2015 - 02/28/2017
 
Title:
Pilot Study of Decitabine and Vorinostat with Chemotherapy in Relapse ALL
Source:
Rally Foundation
Role:
Michael Burke
PI:
Michael Burke
Dates:
04/01/2015 - 03/31/2016
 
Title:
Pilot Study of Decitabine and Vorinostat with Chemotherapy in Relapse ALL
Source:
Rally Foundation for Childhoof Cancer Research Grant
Role:
Principal Investigator
PI:
Michael Burke, MD
Dates:
04/01/2015 - 03/31/2016
Direct Funds:
$50,000
 
Title:
A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease
Source:
TeamConnor Childhood Cancer Foundation
Role:
Principal Investigator
PI:
Michael Burke
Dates:
01/01/2016 - 12/31/2016
Direct Funds:
$35,000
 
Title:
Investigating Clofarabine, Cyclophosphamide and Etoposide for Children and Adolescents with Acute Leukemia and Minimal Residual Disease
Source:
Children’s Research Institute - Leukemia Bridging Study-Team Connor
Role:
PI
PI:
Michael Burke
Dates:
01/01/2016 - 12/31/2016
 
Title:
Epigenetic Reprogramming in Relapse AML
Source:
Bear Necessities Pediatric Cancer Foundation
Role:
PI
PI:
Michael Burke
Dates:
07/01/2016 - 06/30/2018
Direct Funds:
$25,000
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Burke M, "Emergency Department Presentations of Oncologic Diagnoses.", Hennepin County Medical Center, Minneapolis, Minnesota, 09/04/2006
Burke M, "Evaluation of Anemia in the Outpatient Setting.", Buffalo, Minnesota, 03/12/2007
Burke M, "Past, Present and Future of Childhood Leukemia.", Pediatric Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 08/29/2007
Burke M, "Acute Lymphoblastic Leukemia.", University of Minnesota 10th Annual Nursing Conference, Minneapolis, Minnesota, 11/08/2007
Burke M, "Lead Induced Anemia.", Family Medicine Update 2008, Minneapolis, Minnesota, 05/13/2008
Burke M, "Guidelines for Post-Hematopoietic Cell Transplant (HCT) Dasatinib in Ph+ Leukemia.", University of Minnesota BMT Conference, Minneapolis, Minnesota, 06/02/2008
Burke M, "Pediatric & Childhood Lymphomas.", 5th Annual Minnesota Lymphoma Workshop, Lymphoma Research Foundation, Minnesota, 10/18/2008
Burke M, "Wilm's Tumor.", 11th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 11/06/2008
Burke M, "When the Tide Turns in Pediatric Leukemia, 12th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 11/12/2009
Burke M, "Salvaging the Relapsed Leukemia Patient.", University of Minnesota Pediatric Intensive Care Conference, University of Minnesota, Minneapolis, Minnesota, 03/29/2010
Burke M, "Anemia with a Vegetarian Diet.", University of Minnesota Topics and Advances in Pediatrics, Minneapolis, Minnesota, 06/10/2010
Burke M, "Anemia in Today's FP Clinic Setting." Annual Family Medicine Update, Topics & Advances in Pediatrics, Minneapolis, Minnesota, 06/10/2010
Burke M, "When the Tide Turns in Pediatric Leukemia.", 13th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 11/13/2010
Burke M, "Epigenetics in Leukemia - Changing the Relapse Signature.", Children's Hospital Pediatric Research Seminar, University of Minnesota Amplatz, Minneapolis, Minnesota, 11/14/2011
Burke M, "Genetic Mutations in Childhood ALL - How they change the game.", 14th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 01/26/2012
Burke M, "Lower cyclosporine A (CSA) exposure after umbilical cord blood transplantation in acute leukemia is associated with lower survival but not relapse.", University of Minnesota BMT Conference, Minneapolis, Minnesota, 05/14/2012
Burke M, How to Recognize Leukemia and New Advances in Treatment.", Topics & Advances in Pediatrics, Minneapolis, Minnesota, 06/07/2012 - 06/08/2012
Burke M, "Can we manipulate gene expression to control leukemia?" University of Minnesota and People's Republic of China: Health Connections Symposium., University of Minnesota BMT Conference, Minneapolis, Minnesota, 10/08/2012
Burke M, "Meaning and clinical implication of MRD and remission status in adult and pediatric acute leukemia." University of Minnesota BMT Conference, University of Minnesota BMT Conference, Minneapolis, Minnesota, 11/19/2012
Burke M, "COG AALL1131 High Risk and Very High Risk B-ALL.", 15th Annual Nursing Conference, Minneapolis, Minnesota, 01/17/2013
Burke M, Raising the Awareness of AYA Leukemia Outcomes, First Annual Adolescent and Young Adult Cancer Symposium, Milwaukee, WI, 10/23/2013
Burke M, Raising the Awareness of AYA Leukemia Outcomes, Third Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 03/08/2014
Burke M, Epigenetics in Acute Leukemia, Hematologic Malignany and Transplantation Conference, Medical College of Wisconsin, 04/24/2014
Burke M, Childhood Leukemia, HOT Nursing Education Day, Children's Hospital of Wisconsin, 11/12/2014
Burke M, Reversing Chemoresistance in Acute Leukemia, Children’s Research Institute Seminar Series, Children’s Hospital of Wisconsin, Milwaukee, WI, 09/14/2018
Burke M, Understanding the Leukemia Niche in Acute Myeloid Leukemia, Targeting with IL-12, Northwestern Mutual Cancer Symposium, Miller Park, Milwaukee, WI, 05/09/2019
M Burke, "Emerging Therapies and Survivorship in Pediatric ALL; Treatment of ALL in Children – Where We Have Been and Where Are We Going.", Leukemia & Lymphoma Society, Virtual Program, 09/15/2020
 
National
Burke M, "The use of the tyrosine kinase inhibitor (TKI) imatinib as post-allo-HCT prophylaxis in children with Ph+ ALL.", Oncology Strategy Session of Annual PBMTC Meeting, Dallas, TX, 2009
Burke M, "A phase II study of recombinant immunotoxin HA22 in children with relapsed ALL and MRD positivity prior to allo-HCT.", Oncology Strategy Session, Annual PBMTC Meeting 2009, Dallas, TX., 2009
Burke M, "Changing the Approach to Relapse Leukemia--Epigenetic Alterations.", Northwestern University Children's Memorial Hospital, Chicago, Illinois, 07/09/2010
Burke M, "Oncolytic Virus Trial.", Children's Neuroblastoma Cancer Foundation, Chicago, Illinois, 07/10/2010
Burke M, "Treatment of newly diagnosed high risk B-precursor ALL - AALL1131.", Children's Oncology Group Fall Meeting Acute Lymphoblastic Leukemia (ALL) General Session, Dallas, Texas, 09/2010
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrines features - ADVL0911.", Children's Oncology Group Fall Meeting Developmental Therapeutics (DVL) General Session, Dallas, Texas, 09/2010
Burke M, "Addressing the Challenges of Relapse Leukemia.", Pediatric Grand Rounds - Blank Children's Hospital, Des Moines, Iowa, 04/22/2011
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features - ADVL0911.", Children's Oncology Group Fall Meeting, Developmental Therapeutics (DVL) General Session, Atlanta, Georgia, 09/2011
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Children's Oncology Group Fall Meeting, Acute Lymphoblastic Leukemia (ALL) General Session, Atlanta, Georgia, 09/2011
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Children's Oncology Group Fall Meeting, Clinical Research Associate (CRA) General Session, Atlanta, Georgia, 09/2011
Burke M, "A Phase I Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornovirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features.", CTEP Early Drug Development Meeting, Bethesda, Maryland, 10/03/2011
Burke M, "Clinical Development of Epigenetic Therapy in Childhood ALL: Reprogramming ALL Blasts to Reverse Chemoresistance.", ASPHO Meeting, New Orleans, Louisiana, 05/11/2012
Burke M, "Minimal Residual Disease Case Studies", Medical Science Liaison Education Summit, Jazz Pharmaceuticals, Philadelphia, PA, 07/16/2012 - 07/19/2012
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Children's Oncology Group Fall Meeting, Acute Lymphoblastic Leukemia (ALL) General Session, Atlanta, Georgia, 09/2012
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features - ADVL0911.", Children's Oncology Group Fall Meeting, Developmental Therapeutics (DVL) General Session, Atlanta, Georgia, 09/2012
Burke M, "Clinical development of epigenetic therapy in childhood ALL: reprogramming ALL blasts to reverse chemotherapy resistance.", Pediatric Tumor Board - Nationwide Children's Hospital, Columbus, Ohio, 10/26/2012
Burke M, "Clinical development of epigenetic therapy in childhood ALL: reprogramming ALL blasts to reverse chemotherapy resistance.", Pediatric Tumor Board, Children's Hospital of Wisconsin, Milwaukee, WI, 11/08/2012
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Acute Lymphoblastic Leukemia (ALL) General Session, Children's Oncology Group Spring Meeting, Minnesota, 04/10/2013
Burke M, "Childhood Cancers: To Transplant or Not to Transplant - Pediatric Philadelphia-positive (Ph+) Acute Lymphoblastic Leukemia.", ASCO Annual Meeting, Chicago, IL, 06/02/2013
Burke M, "High-Risk and Very High-Risk ALL", Jazz Pharmaceuticals Symposium: Oncology University - All About Acute Lymphoblastic Leukemia, Chicago, IL, 08/01/2013
Burke M, “Understanding the Landscape of Relapsed ALL”, ALL Advisory Board Meeting, Onyx Pharmaceuticals, San Francisco, CA, 09/27/2013
Burke M, A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Acute Lymphoblastic Leukemia (ALL) General Session, Children's Oncology Group Fall Meeting, Dallas, TX, 10/09/2013
Burke M, “Allogeneic hematopoietic cell transplantation outcomes for pediatric T-ALL: New and Old.”, Stem Cell Transplant in ALL Session, Children’s Oncology Group Fall Meeting, Dallas, TX, 10/10/2013
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Chicago, IL, 02/15/2014
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Chicago, IL, 02/18/2014
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Chicago, IL, 02/25/2014
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Fargo, ND, 04/22/2014
Burke M, “Protein-Based Therapeutic Immunogenicity: Clinical Implications.”, Pittsburgh, PA, 04/30/2014
Burke M, “Protein-Based Therapeutic Immunogenicity: Clinical Implications.”, Charlottwsville, VA, 05/13/2014
Burke M, “Protein-Based Therapeutic Immunogenicity: Clinical Implications.”, Broadview Heights, OH, 05/20/2014
Burke M, The Role of Erwinaze (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Charlottesville, VA, 07/15/2014
Burke M, The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Peoria, IL, 07/30/2014
Burke M, The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Phoenix, AZ, 09/08/2014
Burke M, The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Santa Barbara, CA, 09/09/2014
Burke M, The Role of Erwinaze (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia, Charleston, SC, 10/13/2014 - 10/14/2014
Burke M, Understanding the Landscape to Relapse ALL, Philadelphia, PA, 10/21/2014
Burke M, "Changing the Approach to Relapse ALL – one methylated histone at a time”, Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 01/13/2015
Burke M, “Erwinase – asparaginase Erwinia chrysanthemi”, Live National Broadcast, New York, NY, 01/15/2015
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Webinar, 02/10/2015
Burke M, Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131, ASCO Annual Meeting - Oral Presentation, Chicago, IL, 05/2015
Burke M, “Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) n the very high risk (VHR) stratum of patients with newly diagnosed high risk B lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131”, ASCO Annual Meeting Oral Presentation, Chicago, IL, 05/2015
Burke M, Changing the Approach to Relapse ALL – one methylated histone at a time, Pediatric Grand Rounds, Doernbecher Children's Hospital, Portland, OR, 09/2015
Burke M, Changing the Approach to Relapse ALL - one Methylated histone at a time, Pediatric Grand Rounds, Doernbecher Children's Hospital, Portland, OR, 11/2015
Burke M, Acute Lumphoblastic Leukemia Clinical Studies 1, American Society of Hematology (ASH) Annual Meeting, Orlando, FL, 2015
Burke M, “New Frontiers: Advances in Stem Cell Therapy for Pediatric ALL: Session Chair and Moderator", ASPHO/PBMTC Educational Meeting, Minneapolis, MN, 05/11/2016
Burke M, "Novel Indications/Considerations of BMT for ALL in CR1", ASPHO/PBMTC Meeting, Minneapolis, MN, 05/11/2016
Burke M, Children's Oncology Group (COG) B-ALL Protocols, An Update, Society of Adolescent and Young Adult Oncology (SAYAO) Meeting, Newport Beach, CA, 11/14/2016
Burke M, What is the Role of Stem Cell Transplant in the New World of Immune-Biopharmaceuticals and CAR-T Cells?, Society of Adolescent and Young Adult Oncology (SAYAO) Meeting, Newport Beach, CA, 11/15/2016
Burke M, Substitution with Cyclophosphamide and Etoposide Does Not Improve Outcome for Children and Young Adults with Very High-Risk B-Lymphoblastic Leukemia: Children’s Oncology Group (COG) Study AALL1131., 49th Congress of the International Society of Paediatric Oncology (SIOP) Meeting, Washington, DC, 10/13/2017
Burke M, Moving to the Age of Personalized Medicine: The COG Experience, Key Note Speaker Catalyst Symposium on Adolescent and Young Adult (AYA) Oncology, UCLA, Los Angeles, CA, 10/20/2017
Burke M, A Closer Look at the Treatment and Toxicity Management of ALL, University of Michigan, Ann Arbor, MI, 08/14/2018
Burke M, A Deeper Response: MRD-Negativity Results from a Study in Adult B-Cell Precursor Acute Lymphoblastic Leukemia., Miami, FL, 08/21/2018
Burke M, A Deeper Response: MRD-Negativity Results from a Study in Adult B-Cell Precursor Acute Lymphoblastic Leukemia., Los Angeles, CA, 09/05/2018
 
International
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, 7th International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada, 06/13/2013
Burke M, Novel epigenetic strategies in North America, New Agents in Leukemia Meeting, Amsterdam, Netherlands, 10/05/2016
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Hannah Lohmeier, Medical College of Wisconsin, 2017 - 2018 Outpatient clinical preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school.
Danielle Olson, Medical College of Wisconsin, 2017 - 2018 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school
 
Clinical/Research Fellows
Nathan Schloemer, MD, Medical College of Wisconsin, 2013 - 2015 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Schloemer with a clinical research project that resulted in a manuscript as 1st author. (PMID 28452856)
Melissa Acquazzino, MD, Medical College of Wisconsin, 2014 - 2016 “A randomized controlled trial investigating topical caphasol for prevention of mucositis in children, adolescent and young adults receiving chemotherapy or head and neck radiation.” Medical College of Wisconsin; Project Mentor
Neel Bhatt, MD, Medical College of Wisconsin, 2016 - 2018 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Bhatt with an invited review article that resulted in a manuscript as 1st author. (Bhatt BS, Phelan R, Burke MJ. The Role of Hematopoietic Stem-Cell Transplantation in First Remission in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review. Journal of Pediatrics Review. 2017 July;5(2):e10831. doi:10.5812/jpr.10831)
Larisa Broglie, MD, Medical College of Wisconsin, 2017 Fellowship Mentor, I provided mentoring with development of a manuscript that resulted in a publication with Dr. Broglie as 1st author.
Lauren Pommert, MD, Medical College of Wisconsin, 2017 - 2019 Fellowship Mentor, I provided research mentoring along with Sid Rao, MD, PhD as well as mentoring Dr. Pommert with an invited book chapter (Critical Care of the Immune Compromised Pediatric Hematology/Oncology Patient) on Acute Leukemia. This work resulted in a Dr. Pommert listed as a co-author.
Kerri Becktell, MD, Medical College of Wisconsin, 2017 - 2019 Fellowship Mentor, I provided mentoring with development of a manuscript that resulted in a publication with Dr. Becktell as 1st author.
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Patrick Chisum, First Year Medical Student, Medical College of Wisconsin, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin, 2013 - 2014 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school
Tyler Lennon, First Year Medical Student, Medical College of Wisconsin, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin, 2014 - 2015 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school
Lauren Barta, First Year Medical Student, Medical College of Wisconsin, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin, 2015 - 2016 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school
 
Clinical/Research Fellows
Vivian Nnebe, MD, University of Minnesota, 2006 - 2009 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Nnebe in identifying her scholarly research fellowship project in the area of benign hematology and working on more efficient studying methods during fellowship.
Troy Lund, MD, University of Minnesota, 2006 - 2009 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Lund in identifying his scholarly research fellowship project in the area of bone marrow transplantation and submitting and receiving a St. Baldrick’s Fellowship Research Grant.
Heather Stefanski, MD, University of Minnesota, 2007 - 2010 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Stefanski in identifying her scholarly research fellowship project in the area of bone marrow transplantation and submitting and receiving a St. Baldrick’s Fellowship Research Grant.
Jill Beck, MD, University of Minnesota, 2007 - 2010 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Beck in identifying her scholarly research fellowship project in the area of bone marrow transplantation and mentoring her with 2 clinical research projects which both resulted in manuscripts with Dr. Beck as 1st author (PMID: 20856210, PMID: 19908296)
Jennifer McCormack, MD, University of Minnesota, 2008 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. McCormack in identifying her scholarly research fellowship project in the area of acute myeloid leukemia.
Leslie Mortland, MD, University of Minnesota, 2008 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Mortland in identifying her scholarly research fellowship project in the area of acute myeloid leukemia.
Andrew Dietz, MD, University of Minnesota, 2008 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Dietz in identifying his scholarly research fellowship project in the area of survivorship and bone marrow transplantation.
Heather Bechtel, MD, University of Minnesota, 2009 - 2012 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Bechtel in identifying her scholarly research fellowship project in the area of benign hematology as well as working on more efficient studying methods during fellowship.
Nicole Karras, MD, University of Minnesota, 2009 - 2012 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Karras in identifying her scholarly research fellowship project in the area bone marrow transplantation.
Christina Ross, MD, University of Minnesota, 2010 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Ross in identifying her scholarly research fellowship project in the area of leukemia cytogenetics.
Lucie Turcotte, MD, University of Minnesota, 2010 - 2012 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Turcotte in identifying her scholarly research fellowship project in the area of leukemia epidemiology.
Maggie Skrypek, MD, University of Minnesota, 2011 - 2013 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Skrypek in identifying her scholarly research fellowship project in the area of neuro-oncology.
Jennifer Orozco, MD, University of Minnesota, 2011 - 2013 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Orozco in identifying her scholarly research fellowship project in the area of osteosarcoma.
Adam Lamble, MD, Oregon Health & Science University, 2016 - Present Career Mentor, I provided career mentoring as well as mentoring Dr. Lamble with grant and manuscript submissions and provided opportunities to review manuscript submissions as an ad hoc journal reviewer. (PMID 28686179)
Sneha Tandon, MD, Pediatric Leukemia/Lymphoma Fellow Toronto Sick Kids, 2019 ASPHO Mentor/Mentee Program
 
Residents
Julie Bennett, MD, University of Minnesota, 2009 - 2012
Nathan Gossai, MD, University of Minnesota, 2011 - 2014, Mentored Dr. Gossai in 3 clinical research projects which all led to manuscripts in which he was the first author (24317126) and second author (PMID 24185590, 22960388).
Vanessa McFadden, MD, Children's Hospital of Wisconsin, 2014 - 2016 Faculty Mentor, Pediatric Intern/Resident
Daren Diiorio, MD, Children's Hospital of Wisconsin, 2016 - 2017 Faculty Mentor, Pediatric Intern/Resident
Victor Redmon, MD, Children's Hospital of Wisconsin, 2017 - 2018 Faculty Mentor
 
Faculty
Robyn Dennis, MD, Nationwide Children's Hospital - Columbus, OH, 2012 - 2015 Faculty Mentor, I provided career mentoring for Dr. Dennis.
Sarah Lo, MD, Cornell University, NY, 2012 - 2013 Faculty Mentor, I provided career mentoring for Dr. Lo.
Agne Taraseviciute, MD, Children's Hospital of Los Angeles, 2017 - Present Faculty Mentor, I provide career mentoring for Dr. Taraseviciute which included co-authors on a manuscript and assisting her through a job change (Seattle to Children’s Hospital of Los Angeles)
 

AD-HOC MANUSCRIPT REVIEW: 98 MANUSCRIPT REVIEWS:
2017 - Present Acta Pharmacologica Sinica (1); American Journal of Hematology (1); American Journal of Transplantation (1); Annals of Hematology (1); Annals of Transplantation (1); Advances and Applications Current Cancer Drug Targets (1); Biology of Blood and Marrow Transplantation (10); Blood (3); Blood Reviews (3); Bone Marrow Transplantation (2); British Journal of Cancer (1); British Journal of Haematology (1); Cancer (1); Clinical Advances in Hematology & Oncology (1); Clinical Pharmacology (1); European Journal of Pharmacology (2); Haematologica (1); International Journal of Nanomedicine (1); Frontiers in Oncology (1), Journal of Clinical Medicine (1), Journal of Clinical Oncology* (16); Journal of Pediatric Hematology and Oncology (12); Leukemia (1); Leukemia & Lymphoma (3); Leukemia Research Reports (1), Medical Epigenetics (1), New England Journal of Medicine (3), Pediatric Blood and Cancer (20), Pediatric Transplantation (1), PLOS One (1) * Selected to Expedited Reviewer Program for Journal of Clinical Oncology

CONCORTIA AND INDUSTRY CLINICAL TRIALS:
2010 - 2011 Children’s Oncology Group (COG) COG AALL07P4: A Pilot Study of Intravenous EZN-2285 (CS-PEG E. Coli L-Asparaginase, IND# 100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL), UMN Institutional PI
2013 - 2015 TACL Consortium: A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies, CHW Institutional PI .
2013 - 2015 TACL Consortium: A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL, Study Chair.
2013 - 2015 TACL Consortium: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in Relapse T-ALL): A Joint Study of TACL, POETIC and ITCC.
2013 - 2015 Pfizer Expanded Access Myelotarg Protocol for Treatment of Patients with Relapsed/Refractory AML, CHW Institutional PI.
2013 - 2014 TACL Consortium: A Phase I Study of 5-Azacytidine in Combination with Chemotherapy for Children with Relapsed or Refractory ALL or AML, CHW Institutional PI.
2015 - Present TACL/AMGEN: A Phase Ib/II Study of Carfilzomib in Combination with UK ALLR3 Induction Backbone in Children with Relapsed or Refractory ALL, Study Co-Chair.
2016 - 2017 DFCI KPT-330: A Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML, CHW Institutional PI.
2016 - 2019 TACL Consortium: A Phase I Trial of Temsirolimus in Combination with Etoposide and clophosphamide in Children with Relapsed ALL and NHL, CHW Institutional PI.
2016 - 2020 DFCI-MTT: Matched Targeted Therapy Recommendation for Patients with Recurrent,Refractory or High-Risk Leukemias, CHW Institutional PI.
2017 - Present TACL Consortium: A Pilot Study of Vincristine Sulfate Liposome Injection in Combination with UK ALLR3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapse ALL, CHW Institutional PI.
2017 - 2020 TACL Consortium: Epigenetic Reprogramming in Relapse AML: A phase I study of decitabine and vorinostat followed by FLAG in children and young adults in relapsed/refractory AML, Study Chair

CONSULTING POSITIONS:
2009 - Present Best Doctors InterConsultation(Pediatric Hematology/Oncology)
2014 - Present JAZZ Pharmaceuticals – Speaker Bureau for Pediatric Acute Lymphoblastic Leukemia
2017 - Present Shire Pharmaceuticals - Speaker Bureau and Consultant for Pediatric Acute Lymphoblastic Leukemia
2018 - Present AMGEN Pharmaceuticals - Speaker Bureau and Consultant for Pediatric Acute Lymphoblastic Leukemia
2020 - Present CASSIOPEIA Phase II Children’s Oncology Group Trial (AALL1721) Data Safety Monitoring Committee (DSMC) Chair

DEVELOPMENT OF LOCAL RESEARCH CLINICAL TRIALS:
2007 - 2013 Cancer Experimental Therapeutics Initiative Program (CETI): MT2008-29R A Therapeutic Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory ALL or LL, University of Minnesota, Minneapolis, MN, Study Chair.
2008 - 2009 University of Minnesota Fetal Cells in the Maternal Circulation: A Childhood Leukemia Study, Principal Investigator
2008 - 2013 University of Minnesota Leukemia and MDS Tissue Bank, Principal Investigator
2009 - 2012 Cancer Experimental Therapeutics Initiative Program (CETI): MT2008-33R A Therapeutic Trial of Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory ALL, Study Chair. University of Minnesota, Minneapolis, MN.
2013 - Present A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents and Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease, Study Chair. Medical College of Wisconsin/Children’s Hospital of Wisconsin, Milwaukee, WI
2013 - Present Treatment Effects in Children and Adolescent/Young Adults with Leukemia or Lymphoma, Children’s Hospital of Wisconsin, Milwaukee, WI. Principal Investigator.
2014 - Present Epigenetic Reprogramming in Relapse AML: A Phase I Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF in Children and Young Adults with Relapsed/Refractory AML, Children’s Hospital of Wisconsin, Milwaukee, WI, Study Chair.

INVITED GRANT REVIEWER:
2015 - 2018 Rally Foundation
2016 - 2018 St. Baldrick's Foundation
2016 - 2018 Alex's Lemonade Stand Foundation for Childhood Cancer
2017 - 2018 Vince Lombardi Cancer Foundation
2018 Pediatric Cancer Research Fund (PCRF)

INVITED MANUSCRIPT EDITORIAL ARTICLES (PEER REVIEWED):
01/2016 Burke MJ. Minimal residual disease in NPM1-mutated AML. New England Journal of Medicine 2016 January 20. PubMed PMID:26789634
07/2018 Burke MJ. The addition of IKZF1 deletion in risk stratification for children with newly diagnosed B-acute lymphoblastic leukemia leads to improved survival: Results of the Malaysia-Singapore ALL 2010 study. Journal of Clinical Oncology July 2018. Audio PodCast: https://urldefense.proofpoint.com/v2/url?u=http-3A__ascopubs.org_journal_jco&d=DwIGaQ&c=aFamLAsxMIDYjNglYHTMV0iqFn3z4pVFYPQkjgspw4Y&r=K4fL9T8q6SIoC7T_CXzgSQ&m=yZTM8eU4CVXdm2zbe8BK0AJhrhSzcRtZ29_-8ixm2iU&s=DQV8fI1-0UE32wdFt7uncYTM50ttIjUTk0xIjC2IRYc&e=.

INVITED MANUSCRIPT REVIEW ARTICLES (PEER REVIEWED):
06/15/2010 Burke MJ. Recent Pharmacological Advances in the Treatment of Acute Lymphoblastic Leukemia. Clinical Medicine Insights: Therapeutics. 2010 June 15.
07/05/2010 Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep. 2010 Jul;5(3):157-62. Review. PubMed PMID: 20446122.
01/2014 Thakar MS, Talano JM, Tower RL, Kelly ME, Burke MJ. Indications for Transplantation in Childhood Acute Leukemia and the Impact of Minimal Residual Disease on Relapse: A Review. Clinical Practice. January 2014.
02/2014 Burke MJ. Profile of Imatinib in Pediatric Leukemia. Pediatric Health, Medicine and Therapeutics. February 2014.
05/14/2014 Burke MJ, Bhatla T. Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia. Frontiers in Pediatric Oncology Research. May 2014
07/2014 Burke MJ. How to Manage Asparaginase Hypersensitivity in Acute Lymphoblastic Leukemia. Future Oncology. 2014 Jul 1:1-13.[Epub ahead of print] PubMed PMID 24983955
11/30/2015 Erker C, Harker-Murray P, Burke MJ. Emerging Immunotherapy in Pediatric Lymphoma. Future Oncology. 2015 Nov 30. 12(2):257-70 PubMed PMID 26616565
04/2016 Burke MJ. Oncolytic Seneca Valley Virus (SVV-001): past perspectives and future directions. Oncolytic Virotherapy. Accepted April 2016
05/14/2016 Burke MJ, Bhatla T. Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia. Frontiers in Pediatric Oncology Research. 2014 May 14;2:42 PubMed PMID 24860797
09/06/2016 Burke MJ. Oncolytic Seneca Valley Virus (SVV-001): past perspectives and future directions. Oncolytic Virotherapy. 2016 Sep 6;5:81-9. PubMed PMID 27660749
02/2017 - Present Bhatt BS, Phelan R, Burke MJ. Pediatric Acute Lymphoblastic Leukemia: The Role of Hematopoietic Stem-Cell Transplantation in First Remission. Submitted to Journal of Pediatrics Review, February 2017
03/2017 - Present Bhatt BS, Phelan R, Burke MJ. Pediatric Acute Lymphoblastic Leukemia: The Role of Hematopoietic Stem-Cell Transplantation in First Remission. Accepted to Journal of Pediatrics Review, March 2017
07/07/2017 Lamble A, Phelan R, Burke M. When Less is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia. J Clin Med. 2017 Jul 7;6(7). PubMed PMID 28686179.

NATIONAL CHILDREN'S ONCOLOGY GROUP TRIALS (NOT SUPPORTED BY GRANT FUNDING):
2010 - 2013 Children's Oncology Group (COG), COG AALL03B1:Classification of Acute Lymphoblastic Leukemia, UMN Institutional PI.
2010 - 2011 Children’s Oncology Group (COG) COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia, Institutional PI
2010 - 2011 Children’s Oncology Group (COG)COG AALL07P4 A Pilot Study of Intravenous EZN-2285 (CS-PEG E. Coli L-Asparaginase, IND# 100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL), Institutional PI
2010 - 2011 Children’s Oncology Group (COG) COG AALL07P2 - Erwinia Asparaginase, Institutional PI
2010 - 2013 Children’s Oncology Group (COG):COG AAML0531, UMN Institutional PI
2010 - 2013 Children’s Oncology Group (COG) COG AAML0431: The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years, UMN Institutional PI
2010 - 2013 Children's Oncology Group (COG) COG AALL0434: Intensified Methotrexate, Nelarabine and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia, UMN Institutional PI.
2010 - 2013 Children’s Oncology Group (COG) AALL06N1 A Study of Neurocognitive Function in Children Treated for ALL, UMN Institutional PI
2010 - 2013 Children’s Oncology Group (COG)COG AALL08B1: Classification of Acute Lymphoblastic Leukemia, UMN Institutional PI.
2010 - 2013 Children’s Oncology Group (COG) COG AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807), UMN Institutional PI
2010 - 2011 Children’s Oncology Group (COG) COG AALL0232 High Risk B-precursor Acute Lymphoblastic Leukemia, Institutional PI
2010 - 2013 Children’s Oncology Group (COG) COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples, UMN Institutional PI
2010 - 2013 Children’s Oncology Group (COG) COG AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies, UMN Institutional PI
2013 - 2015 Children’s Oncology Group (COG) COG AAML1321: A Multi-Center, Open Label, Non-Controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients with Newly Diagnosed Ph+ CML in Chronic Phase (CP) or with Ph+ CML in CP or Accelerated Phase Resistant or Intolerant to either Imatinib or Dasatinib, CHW Institutional PI.
2015 - 2019 Children’s Oncology Group (COG) COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumumab in 1st Relapse B-ALL, CHW Institutional PI.
2015 - Present Children’s Oncology Group (COG) COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolesents, CHW Institutional PI.
2015 - 2019 Children’s Oncology Group (COG) COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib on an ABFM Backbone in Newly Diagnosed T-ALL and T-LL, CHW Institutional PI.
2016 - Present Children’s Oncology Group (COG) COG AAML1531: Risk-stratified Therapy for AML in Down syndrome, CHW Institutional PI.
2016 - 2019 Children’s Oncology Group (COG) COG AAML1421: A Phase I/II Study of CPX-351 Alone Followed by FLAG for Children with Relapsed AML, CHW Institutional PI.
2016 - Present Children’s Oncology Group (COG) COG AAML1331: A Phase III Study for Patients with Newly Diagnosed APL Using Arsenic Trioxide and ATRA, CHW Institutional PI.
2017 - 2019 Children’s Oncology Group (COG) COG AAML1522: A Phase II, Multicenter, Single-Arm, Open Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide in Pediatric Subjects Ages 1-18 years of Age with Relapsed or Refractory AML, CHW Institutional PI.
2017 - Present Children’s Oncology Group (COG) COG AALL1521: A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant ALL, CHW Institutional PI.
2018 - Present Children’s Oncology Group (COG) COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy, Study Committee Member

NATIONAL INVITED WEBINAR PRESENTATIONS:
01/25/2011 Burke, Michael, “Oncolytic Virotherapy for Pediatric Tumors - Seneca Valley Virus”. National Webinar- Solving Kid’s Cancer, January 25, 2011.
01/26/2011 Burke, Michael,“Implications for Nursing Practice in Pediatric Leukemia.” National Webinar – The National Children’s Cancer Society, January 26, 2011.
03/2014 Burke, Michael, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.” National Webinar – JAZZ Pharmaceuticals, March 25, 2014
02/10/2015 “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.” Webinar.
11/24/2015 “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.” Webinar.


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer. 2007 Aug;49(2):196-8. PubMed PMID: 17417796.
2. Burke MJ, Cohn SL. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer. 2008 Mar;50(3):679-80. PubMed PMID: 16900484.
3. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009 Jan;43(2):107-13. PubMed PMID: 18776928.
4. Burke MJ, Dayton V. Treatment of a CNS relapse while on therapy for Burkitt lymphoma. Pediatr Blood Cancer. 2009 Feb;52(2):290-2. PubMed PMID: 18937319.
5. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Aug;44(3):169-74. PubMed PMID: 19204709.
6. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 5;114(19):4293-9. PubMed PMID: 19706886
7. Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2009 Dec 15;53(7):1289-94. PubMed PMID: 19731318.
8. Burke MJ, Willert J, Desai S, Kadota R. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. Pediatr Blood Cancer. 2009 Dec;53(6):992-5. PubMed PMID: 19621426.
9. Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer. 2010 Mar;54(3):490-1. PubMed PMID: 19908296.
10. Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2010 Sep;16(9):1237-44. PubMed PMID: 20302960.
11. Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010 Nov 11;116(19):4007-15. PubMed PMID: 20671124
12. Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR. Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone Marrow Transplant. 2011 Mar;46(3):368-71. PMID: 20548337.
13. Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011 May 12;117(19):5261-3. PubMed PMID: 21403127
14. Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant. 2011 Jun;17(6):831-40. PubMed PMID: 20831896.
15. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant. 2011 Jul;46(7):950-5. PMID: 20856210.
16. Burke MJ, McCormack J, Qing Q, Verneris M. Allogeneic hematopoietic cell transplantation outcomes for children and young adults with treatment-related myelodysplastic syndrome or acute myeloid leukemia. Journal of Hematological Malignancies. 2011 December;Vol.1(1):6-14.
17. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012 May 31;119(22):5201-10. PMID: 22496163
18. Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant. 2012 Jun;18(6):963-8. PubMed PMID: 22430088.
19. Burke MJ, Lindgen B, Verneris MR. Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. Pediatr Blood Cancer. 2012 Jun;58(6):840-5. PubMed PMID: 21796765.
20. Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012 Jun;18(6):930-6. PubMed PMID: 22108570.
21. Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel BJ, Stempak D, Balis FM, Blaney SM. A Phase I Trial and Pharmacokinetic Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias. Clin Cancer Res. 2012 Nov 1;18(21):6011-22. PubMed PMID: 22962440.
22. Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, Macmillan ML, Stefanski HS, Weisdorf DJ, Verneris MR. Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1):138-42. PubMed PMID: 22960388.
23. Smith AR, Christiansen EC, Wagner JE, Qing C, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR. Early Hematopoietic Stem Cell Transplant is Associated with Favorable Outcomes in Children with MDS. Pediatric Blood and Cancer 2013 Apr;60(4):705-10. PubMed PMID: 23152304.
24. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation 2013. Jul;19(7):1021-5 PubMed PMID: 23567175.
25. Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C. How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. American Journal of Hematology 2013 Sept;88(9):826-7 PubMed PMID: 23737091.
26. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplantation 2013 Nov;48(11):1415-20. PubMed PMID 23933764
27. Burke MJ, Gossai N, Cao Q, MacMillan ML, Warlick E, Verneris MR. Similar outcomes between adolescent / young adults and children with AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 2014 Feb;49(2):174-8 PubMed PMID: 24185590.
28. Pratt JA, Stricherz MK, Verghese PS, Burke MJ. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population treated for neutropenic fever. Pediatric Blood and Cancer.2014 Feb;61(2):366-8 PubMed PMID 24038944.
29. Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ. A clofarabine-based bridging regimen in patients with acute lymphoblastic leukemia (ALL) and persistent minimal residual disease (MRD). Bone Marrow Transplantation. 2014 Mar;49(3):440-2 PubMed PMID: 24317126.
30. Burke MJ*, Lamba JK*, Pounds S, Cao X, Ghodke-Puranak Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL). Am J Hematol. 2014 Sep;89(9):889-95. PubMed PMID 24891274. *authors contributed equally to the manuscript
31. Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM. Phase I trial of Seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children’s Oncology Group. Pediatric Blood and Cancer 2015 May;62(5):743-50. PubMed PMID 25307519
32. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Guilcher GMT, Hayashi RJ, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah NN, Thiel E, Kitko CL. Transplant Outcomes for Children with T-Cell Acute Lymphoblastic Leukemia in Second Remission: A Report of the CIBMTR®. Biology of Blood and Marrow Transplantation 2015 Dec;21(12):2154-9. PubMed PMID 26327632
33. Lu BY, Thanawala SU, Zochowski K, Burke MJ, Carroll WL, Bhatla T. Decitabine enhances chemosensitivity of ETP-ALL but no other T-ALL subtypes. Leukemia & Lymphoma - 2016 Jan 4:1-4 PubMed PMID: 26726842
34. Rodriguez V, Kairalla J, Salzer W, Raetz E, Loh M, Carroll A, Heerema NA, Wood B, Borowitz MJ, Burke MJ, Asselin B, Devidas M, Winick NW, Carroll WL, Hunger SP, Dreyer Z. A pilot study of intensified PEG-asparaginase in high risk acute lymphoblastic leukemia: Children’s Oncology Group Study AALL08P1. Journal of Pediatric Hematology-Oncology 2016 Aug;38(6):409-17. PubMed PMID: 27299599.
35. Burke MJ and Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for Acute Lymphoblastic Leukemia. Leukemia and Lymphoma 2016 Aug 22:1-12 PubMed PMID: 27546298
36. Burke MJ. Oncolytic Seneca Valley Virus: current perspectives. Oncolytic Virother. 2016 Sep 6;5:81-9 PubMed PMID 27660749
37. Gu Z, Li Y, Liu Y, Reshmi S, Roberts K, Harvey RC, McCastlain K, Payne-Turner D, Churchman M, Iacobucci I, Shao Y, Easton J, Chen I, Valentine M, Mungall K, Mungall A, Ma Y, Moore R, Marra M, Eileen Stonerock, Julie Gastier-Foster, Meenakshi Devidas, Yunfeng Dai, Brent Wood, Michael Borowitz, Eric Larsen, Maloney K, Mattano Jr LA, Angiolillo A, Salzer WL, Burke MJ, Rambaldi A, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger S, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Gerhard DS, Loh M, Hunger S, Mullighan C. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukemia. Nature Communications 2016 Nov 8;7:13331. PubMed PMID: 27824051
38. Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Pineros V, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS. Treatment Related Adverse Events Associated with a Modified UK ALLR3 Induction Chemotherapy Backbone for Childhood Relapsed/Refractory Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer 2016 Nov;63(11):1943-8. PubMed PMID: 27437864
39. Burke MJ and Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for Acute Lymphoblastic Leukemia. Leukemia and Lymphoma 2017 Mar;58(3):540-551. PubMed PMID: 27546298
40. Fisher JB, McNulty M, Burke MJ, Crispino J, Rao S. Cohesin Mutations in Myeloid Malignancies. Trends in Cancer. 2017 Apr;3(4):282-293. PubMed PMID 28626802
41. Robin AJ, Peterson JF, Grignon Jr. JW, Gheorghe G, Burke MJ, VanTuinen P. Identification of High-Risk Cryptic CRLF2 Rearrangements in B-cell Acute Lymphoblastic Leukemia Utilizing an FGFR3/IGH Dual-Color Dual-Fusion DNA Probe Set. Journal of Pediatric Hematology-Oncology 2017 May;39(4):e207-e210 PubMed PMID: 27820126
42. Reshmi S, Harvey R, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweilder-McKay, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Targetable Kinase Gene Fusions in High Risk B-ALL: A Study from the Children’s Oncology Group. Blood 2017 Jun 22;129(25):3352-3361 PubMed PMID: 28408464
43. Schloemer NJ, Brickler M, Pan A, Hoffmann R, McFadden V, Block J, Tower RL, Burke MJ. Administration of Dexrazoxane Improves Cardiac Outcomes in Children and Young Adults with Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. Journal of Pediatric Hematology/Oncology 2017 Jul;39(5):e254-e258 PMID: 28452856
44. Bhatt BS, Phelan R, Burke MJ. The Role of Hematopoietic Stem-Cell Transplantation in First Remission in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review. Journal of Pediatrics Review. 2017 July;5(2):e10831. doi:10.5812/jpr.10831
45. Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatric Hematol Oncol 2017 Nov 30:1-10 PubMed PMID:29190164
46. Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM0, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Toxicity Associated with Intensive Post-Induction Therapy Incorporating Clofarabine in the Very High-Risk Stratum of Patients with Newly Diagnosed High Risk B-Lymphoblastic Leukemia: A Report from the Children’s Oncology Group Study AALL1131. Cancer 2018 Mar 15;124(6):1150-1159 PMID: 29266189 *These 2 authors contributed equally as first authors
47. Roberts KG, Reshmi SC, Harvey RC, Chen I, Patel K, Stonerock E, Jenkins H, Dai Y, Valentine M, Gu Z, Zhao Y, Liu Y, Li Y, Zhang J, Payne-Turner D, Devidas M, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Angiolillo A, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Mattano L, Maloney KW, Carroll WL, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Genomic and outcome analyses of Philadelphia chromosome-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood. 2018 Aug 23;132(8):815-824 PMID: 29997224
48. Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer J, Duvall A, Bleyer A. Levocarnitine for Asparaginase-Induced Hepatic Injury: A Multi-Institutional Case Series and Review of the Literature. Leukemia & Lymphoma 2018 Oct;59(10):2360-2368 PMID: 29431566
49. Becktell K, Houser K, Burke MJ. Epigenetic therapy in a patient with Down syndrome and refractory acute myeloid leukemia. Journal of Pediatric Hem Onc. 2019 Jan;41(1):e38-e40 PMID: 29668549
50. Broglie L, Gershan J, Burke MJ. Check-point inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. International Int J Hematol Oncol. 2019 Jan 16;8(1):IJH10 PMID: 30863527
51. Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME. Practice Patterns of Physician Treatment for Pediatric Chronic Myeloid Leukemia (CML). Biol Blood Marrow Transplant. 2019 Feb;25(2):321-327 PMID: 30267760
52. Lu BY, Thanawala SU, Zochowski K, Burke MJ, Carroll WL, Bhatla T. Decitabine enhances chemosensitivity of ETP-ALL but no other T-ALL subtypes. British Journal of Haematology Submitted July 2015
53. Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Leonard A. Mattano Jr LA., Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A. Pegaspargase Hypersensitivity Reaction Rates with Intravenous Infusion versus Intramuscular Injection: Analysis of 34,413 Doses Administered to 16,534 Patients on Children’s Oncology Group (COG) Clinical Trials. Submitted to Journal of Clinical Oncology August 2016 (under revision for submission to Cancer)
54. Pommert L, Margossian S, Burke MJ. Critical care of the pediatric immunocompromised hematology/oncology patient: an evidence-based guide. Text Book; Chapter submitted on Acute Leukemia. February 2018
55. Keating A, Gossai N, Phillips C, Maloney K, Doan A, Bhojwani D, Burke MJ, Verneris MR. Reducing Minimal Residual Disease Prior to Hematopoietic Cell Transplant for Pediatric Patients with Acute Lymphoblastic Leukemia. Accepted to Blood Advances December 2018
56. Taraseviciute A, Broglie L, Phelan R, Bhatt N, Becktell K, Burke MJ. What is the role of hematopoietic cell transplantation for pediatric acute lymphoblastic leukemia in the age of chimeric antigen receptor T-cell therapy? Accepted to Journal of Pediatric Hematology/Oncology December 2018
57. Athale U, Hijiya N, Patterson B, Bergsagel DJ, Andolina J, Bittencourt H, Schultz K, Burke M, Redell M, Kolb E, Johnston D. Management of chronic myeloid leukemia (CML) in children and adolescents: Recommendations from the Children’s Oncology Group CML Working Group. Accepted to Pediatric Blood and Cancer March 2019
58. Taraseviciute A, Broglie L, Phelan R, Bhatt N, Becktell K, Burke MJ. What is the role of hematopoietic cell transplantation for pediatric acute lymphoblastic leukemia in the age of chimeric antigen receptor T-cell therapy? J Pediatr Hematol Oncol. 2019 Apr 9 [Epub ahead of print] PubMed PMID: 30973486
59. Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease free survival for high risk B-lymphoblastic leukemia: Children’s Oncology Group study AALL1131. Accepted to Journal of Clinical Oncology February 2020
60. Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: A TACL pilot study. Clin Cancer Res. 2020 Jan 22 [Epub ahead of print]
61. Rossoff J, Huynh V, Rau RR, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O’Brien MM, Gregory JJ, Van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in pediatric patients with leukemia. Br J Haematol.2020 Apr; 189(2):363-368. Doi: 10.1111/bjh.16338. PMID: 31975387
62. Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease free survival for high risk B-lymphoblastic leukemia: Children’s Oncology Group study AALL1131. J Clin Oncol. 2020 Jun 4:JCO1902892 [Epub ahead of print] PMID: 32496902
63. Yu Q, Zhong X, Chen B, Feng Y, Ma M, Diamond CA, Voeller JS, Kim M, DeSantes KB, Capitini C, Patel N, Hoover-Regan M, Burke MJ, Janko K, Puccetti DM, Ikonomidou C, Li L. Isobaric labeling strategy utilizing 4-plex N, N-dimethyl leucine (DiLeu) tags reveals proteomic changes induced by chemotherapy in cerebrospinal fluid of children with B-cell acute lymphoblastic leukemia. J Proteome Res. 2020 May 27 [Epub ahead of print] PMID: 32396724
64. John Goldberg, Julia Bender, Sima Jeha, Maria Luisa Sulis, Rebecca Gardner, Jessica Pollard, Victor Aquino, Theodore Laetsch, Naomi Winick, Cecilia Fu, Leigh Marcus, Weili Sun, Anupam Verma, Michael Burke, Phoenix Ho, Thomas Manley, Rajen Mody, Wendy Tcheng, Blythe Thomson, Julie Park, Richard Sposto, Yoav Messinger, Nobuko Hijiya, Paul Gaynon, Julio Barredo. A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatric Hematology and Oncology. 27 April 2020 [Epub ahead of print]
65. Pommert L, Liberio N, Ng JS, Egelund TA, Siver MJ, Katzenstein HM, Burke MJ. Concurrent imatinib dosing with high-dose methotrexate clearance in pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2020 May 8 [Epub ahead of print] PMID: 32398599
 
Books, Chapters, and Reviews
1. Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Chapter IV: CML in the Pediatric Population. Burke M and Eldjerou L. Nova Science Publishers, Inc. 2013.
 
Editorials, Letters to Editor, Other
1. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant. 2011 Jul;46(7):950-5. PubMed PMID: 20856210.
2. Burke MJ. Allogeneic hematopoietic cell transplantation provides no benefit for patients with hypodiploidy acute lymphoblastic leukemia. J Clin Oncol. 2019 Apr 1;37(10):763-764 PMID: 30794478
 
Abstracts
1. Burke MJ, Kletzel M, Jacobsohn DA, Duerst RE. Tandem High-Dose Chemotherapy with Peripheral Blood Stem Cell Rescue as Consolidation Therapy for High-Risk (Primary Unresectable Pelvic Tumors or Metastatic Disease) Ewing's Sarcoma Patients Compared to Standard Chemotherapy. ASBMT Annual Meeting. Biology of Blood and Marrow Transplantation February 2005; Vol.11, Issue 2, Supplement 1:85.
2. Burke MJ, Kennedy P, Wang L, Bhatt D, Tse WT. Myogenic Developmental Potential of Hemangioblasts Derived From Mouse Embryonic Stem Cells. American Society of Hematology (ASH) Annual Meeting. Blood November 2005; Vol. 106, Issue 11: 1702.
3. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Impact of Imatinib on Cardiac Toxicity, Relapse and Survival. ASBMT Annual Meeting. Biology of Blood and Marrow Transplantation February 2008; Vol.14, Issue 2, Supplement: 56-57.
4. Burke MJ, Gursahaney A, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Cardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT). ASCO Annual Meeting. Journal of Clinical Oncology May 2008, 26: 7039.
5. Burke MJ, Trotz B, Cao Q, Weigel B, Kumar A, Smith A, Verneris MR. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL). American Society of Hematology (ASH) Annual Meeting. Blood November 2009, Vol.114, Issue 22: 3377.
6. Burke MJ, Lamba J, Weigel B, Bachanova V, Verneris MR, and Miller JS. A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. ASH Annual Meeting Abstracts 120 4307-.2012
7. Bhatla T, Wang J, Morrison D, Jones C, Raetz E, Burke M, Brown P, Loh M, Hunger S, Carroll W. Evolution of the histone code in relapsed acute lymphoblastic leukemia (ALL). Pediatric Blood & Cancer June 2013;60:S40-S40. id: 348982
8. Bhatla T, Blum R, Wang J, Jones CL, Morrison DJ, Raetz EA, Burke MJ, Brown P, Harvey RC, Willman CL, Loh M, Hunger SP, Carroll WL. Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood 2014 124:612; published ahead of print December 5, 2014
9. Sasaki K, Rodriguez II, Kantarjian H, O’Brien S, Jabbour E, Borthakur G, Ravandi F, Burke M, Zweidler-McKay PA, Cortes JE.Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Blood 2014 124:4538; published ahead of print December 5, 2014
10. Sun W, Smith A, Sposto R, Orgel E, Wilkes JJ, Gardner R, Hur M, Pineros V, Tan Y, Rheingold SR, Burke M, Wayne AS. The UK ALLR3 (R3) Chemotherapy Regimen for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events (AEs). Blood 2014 124:3647; published ahead of print December 5, 2014
11. Burke MJ, Gore L, Sposto R, Bhojwani D, Chang BH, DuBois SG, Gaynon PS, Glade-Bender J, Heym KM, Huynh VT, Sulis ML, Pollard JA, Verma A, Brown P. Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Blood 2014 124:3650; published ahead of print December 5, 2014
12. Salzer W, Burke MJ, Larsen EC, Chen S, Gore L, Hilden JM, Loh ML, Raetz E, Winick NJ, Carroll WL, Devidas M, Hunger SP. Incidence of allergic reactions to pegaspargase administered intramuscularly versus intravenously in children and young adults with high risk B-lymphoblastic leukemia: Results of Children's Oncology Group studies AALL0232/AALL1131. Blood. 2015;126(23):1303-1303.
13. Rabin KR, Hitzler J, Rodriguez V, Schore R, Angiolillo A, Burke MJ, Salzer W, Maloney K, Lu X, Devidas M, Loh ML, Raetz E, Hunger SP. Treatment-related mortality in children with Down Syndrome and B-lymphoblastic leukemia: An interim report from the Children's Oncology Group trials AALL0932 and AALL1131. Blood. 2015;126(23):2502-2502.
14. Hardy KK, Winick N, Hostetter SA, Jarel BT, Walsh KS, Annett RD, Embry L, Burke M, Salzer W, Noll RB. Promoting neurocognitive assessment participation in a large, multi-site treatment study of children with newly diagnosed acute lymphoblastic leukemia: a Children's Oncology Group study AALL1131. Proceedings of the American Academy of Pediatrics. 2014: 24579.
15. Salzer WL, Burke M, Devidas M, Gore L, Larsen E, Zaoutis TE, Fisher B, Steinbach W, Hilden J, Loh ML, Winick N, Carroll WL, Raetz E, Sung L, Hunger S. Induction mortality and its association with invasive fungal infections (IFI) in children and young adults with high risk (HR) B-lymphoblastic leukemia (B-ALL): early results from Children’s Oncology Group study AALL1131. Pediatric Blood & Cancer. 2014; 61(S1):4015.
16. Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Michael J. Burke, Patrick Brown, Richard Sposto, Lia Gore, Bill H. Chang, Todd Cooper, Robyn Dennis, Steven DuBois, Rebecca Gardner, Paul Gaynon, Kenneth Heym, Van Thu Huynh, Sima Jeha, Joel Kaplan, Theodore Laetsch, Javier Oesterheld, Maria Luisa Sulis, Anupam Verma, David Ziegler, Alan Wayne. ASH 2017 abstract Blood
17. Burke MJ, Brown P, Sposto R, Gore L, Wayne A. Pilot study of decitabine and vorinostat with chemotherapy for relapsed ALL: A report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Blood. 2016:128(22):2781
18. Hampton OA, Ramos EI, Kakkar N, Junco JJ, Reuther J, Angiolillo A, Schore RJ, Burke MJ, Salzer W, Devidas M, Carroll AJ, Heerema NA, Maloney K, Winick N, Carroll WL, Raetz E, Loh ML, Hunger SP, Jain J, Doddapaneni H, Muzny DM, Wheeler DA, Fisher KE, Lopez-Terrada DH, Roy A, Parsons DW, Rabin KR. Integrated genomic analysis of Down syndrome acute lymphoblastic leukemia reveals recurrent cancer gene alterations and evidence of frequent subclonal driver events. Blood. 2016:128(22):4083.
 

jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a